Literature DB >> 22041375

Successful treatment of immunoglobulin D myeloma by bortezomib and dexamethasone therapy.

Naohiro Sekiguchi1, Naoki Takezako, Akihisa Nagata, Miyuki Wagatsuma, Satoshi Noto, Kazuaki Yamada, Akiyoshi Miwa.   

Abstract

Immunoglobulin D (IgD) myeloma is a rare subtype and it is widely accepted as an aggressive disease. Here, we report a 66-year-old woman with IgD myeloma who had anemia, lumbago, multiple osteolytic lesions and hypercalcemia. The patient refused a blood transfusion because of her beliefs, so we administered bortezomib and dexamethasone (BD) after high-dose dexamethasone therapy. Marked improvement of anemia and elevated serum alkaline phosphatase levels was recognized. After 5 cycles of BD therapy, the patient achieved a stringent complete response according to International Myeloma Working Group Response Criteria. BD therapy might be a feasible and useful treatment option for IgD myeloma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22041375     DOI: 10.2169/internalmedicine.50.5977

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

1.  Impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy.

Authors:  Naohiro Sekiguchi; Kaori Ootsubo; Miyuki Wagatsuma; Kiyoe Midorikawa; Akihisa Nagata; Satoshi Noto; Kazuaki Yamada; Naoki Takezako
Journal:  Int J Hematol       Date:  2014-02-05       Impact factor: 2.490

2.  Immunoglobulin D Multiple Myeloma With Rapidly Progressing Renal Failure.

Authors:  Jwalant Modi; Jeanne Kamal; Ahmad Eter; Suzanne El-Sayegh; Elie El-Charabaty
Journal:  J Clin Med Res       Date:  2015-06-09

3.  Successful treatment of non-IgM lymphoplasmacytic lymphoma by bortezomib-containing regimen: case reports and review of literature.

Authors:  Kenichi Ito; Risa Nishiyama; Kazuhiko Hirano; Kazuaki Yamada; Naohiro Sekiguchi
Journal:  Blood Res       Date:  2019-09-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.